A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5651-5662

  Wang, Li Ting ^a   Liou, Jing Ping ^b   Li, Yu Hsuan ^b   Liu, Yi Min ^b   Pan, Shiow Lin ^b   Teng, Che Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Differentiation; E cadherin; HDAC; MPT0G030; PKC

Indexed keywords

3 [7 AMINO 1 (4 METHOXYBENZENESULFONYL) 2,3 DIHYDRO 1H INDOL 5 YL] N HYDROXYACRYLAMIDE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; MPT 0G030; PROTEIN KINASE C DELTA; PROTEIN P21; UNCLASSIFIED DRUG; UVOMORULIN; VORINOSTAT; CADHERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DIFFERENTIATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; FLUOROMETRY; GENE EXPRESSION REGULATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; RNA TRANSCRIPTION; SOLID TUMOR; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HT 29 CELL LINE; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; CADHERINS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HT29 CELLS; HUMANS; MICE; PROTEIN KINASE C-DELTA; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906234182     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2155     Document Type: Article

References (31)

1. Gloor FJ. The adenoma-carcinoma sequence of the colon and rectum. Soz Praventivmed. 1986; 31(2):74-75.
2. Bolden JE, Peart MJ and Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-784.
3. Witt O, Deubzer HE, Milde T and Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009; 277(1):8-21.
4. Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics: official journal of the DNA Methylation Society. 2008; 3(1):28-37.
5. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP and Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004; 5(5):455-463.
6. Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW and Giardina C. HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog. 2008; 47(2):137-147.
7. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH and Mariadason JM. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006; 281(19):13548-13558.
8. Sengupta S, Muir JG and Gibson PR. Does butyrate protect from colorectal cancer? J Gastroenterol Hepatol. 2006; 21(1 Pt 2):209-218.
9. Koivunen J, Aaltonen V and Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett. 2006; 235(1):1-10.
10. Basu A and Pal D. Two faces of protein kinase Cdelta: the contrasting roles of PKCdelta in cell survival and cell death. TheScientificWorldJournal. 2010; 10:2272-2284.
11. Mischak H, Goodnight JA, Kolch W, Martiny-Baron G, Schaechtle C, Kazanietz MG, Blumberg PM, Pierce JH and Mushinski JF. Overexpression of protein kinase C-delta and-epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem. 1993; 268(9):6090-6096.
12. Perletti GP, Marras E, Concari P, Piccinini F and Tashjian AH, Jr. PKCdelta acts as a growth and tumor suppressor in rat colonic epithelial cells. Oncogene. 1999; 18(5):1251-1256.
13. Perletti G and Terrian DM. Distinctive cellular roles for novel protein kinase C isoenzymes. Curr Pharm Des. 2006; 12(24):3117-3133.
14. Kim YH, Lim JH, Lee TJ, Park JW and Kwon TK. Expression of cyclin D3 through Sp1 sites by histone deacetylase inhibitors is mediated with protein kinase C-delta (PKC-delta) signal pathway. J Cell Biochem. 2007; 101(4):987-995.
15. Mariadason JM, Rickard KL, Barkla DH, Augenlicht LH and Gibson PR. Divergent phenotypic patterns and commitment to apoptosis of Caco-2 cells during spontaneous and butyrate-induced differentiation. J Cell Physiol. 2000; 183(3):347-354.
16. Skoudy A, Llosas MD and Garcia de Herreros A. Intestinal HT-29 cells with dysfunction of E-cadherin show increased pp60src activity and tyrosine phosphorylation of p120-catenin. Biochem J. 1996; 317(Pt 1):279-284.
17. Orchel A, Dzierzewicz Z, Parfiniewicz B, Weglarz L and Wilczok T. Butyrate-induced differentiation of colon cancer cells is PKC and JNK dependent. Dig Dis Sci. 2005; 50(3):490-498.
18. Zhao Y, He D, Stern R, Usatyuk PV, Spannhake EW, Salgia R and Natarajan V. Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin. Cell Signal. 2007; 19(11):2329-2338.
19. Humphries A and Wright NA. Colonic crypt organization and tumorigenesis. Nat Rev Cancer. 2008; 8(6):415-424.
20. Creamer B, Shorter RG and Bamforth J. The turnover and shedding of epithelial cells. I. The turnover in the gastro-intestinal tract. Gut. 1961; 2:110-118.
21. Launay S, Hermine O, Fontenay M, Kroemer G, Solary E and Garrido C. Vital functions for lethal caspases. Oncogene. 2005; 24(33):5137-5148.
22. Cerda SR, Bissonnette M, Scaglione-Sewell B, Lyons MR, Khare S, Mustafi R and Brasitus TA. PKC-delta inhibits anchorage-dependent and-independent growth, enhances differentiation, and increases apoptosis in CaCo-2 cells. Gastroenterology. 2001; 120(7):1700-1712.
23. Semb H and Christofori G. The tumor-suppressor function of E-cadherin. Am J Hum Genet. 1998; 63(6):1588-1593.
24. Reshetnikova G, Troyanovsky S and Rimm DL. Definition of a direct extracellular interaction between Met and E-cadherin. Cell Biol Int. 2007; 31(4):366-373.
25. Tsanou E, Peschos D, Batistatou A, Charalabopoulos A and Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res. 2008; 28(6A):3815-3826.
26. Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12(2):89-103.
27. Gentile A, Trusolino L and Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008; 27(1):85-94.
28. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, Caballero R, Alaminos M, Setien F, Paz MF, Herranz M, Palacios J, Arango D, Orntoft TF, Aaltonen LA, Schwartz S, Jr., et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet. 2006; 38(5):566-569.
29. Witt O, Deubzer HE, Milde T and Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009; 277(1):8-21.
30. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T and Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A. 1999; 96(8):4592-4597.
31. Cohen E, Ophir I and Shaul YB. Induced differentiation in HT29, a human colon adenocarcinoma cell line. J Cell Sci. 1999; 112 ( Pt 16):2657-2666.